BC-1215

an Fbxo3 inhibitor; structure in first source

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

1.	Acute Lung Injury 01/01/2019 - "In this study, we investigated the protective effects of BC-1215 administration, a Fbxo3 inhibitor, on acute lung injury induced by I/R in rats. "
2.	Hyperalgesia 01/01/2021 - "Furthermore, intrathecal administration of BC-1215 (a novel Fbxo3 inhibitor) prevented CARM1 ubiquitination to block K+ channel gene silencing and ameliorate allodynia after nerve injury. " 12/16/2015 - "In contrast, intrathecal administration of BC-1215 (N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]-1,2-ethanediamine) (a novel Fbxo3 inhibitor) prevented SNL-induced Fbxl2 ubiquitination and subsequent TFAF2 de-ubiquitination to ameliorate behavioral allodynia via antagonizing TRAF2/TNIK/GluR1 signaling. "
3.	Lung Injury 01/01/2019 - "Results: BC-1215 significantly attenuated I/R-induced lung edema, indicated by a reduced vascular filtration coefficient, wet/dry weight ratio, lung injury scores, and protein levels in bronchoalveolar lavage fluid (BALF). "
4.	Edema (Dropsy) 01/01/2019 - "Results: BC-1215 significantly attenuated I/R-induced lung edema, indicated by a reduced vascular filtration coefficient, wet/dry weight ratio, lung injury scores, and protein levels in bronchoalveolar lavage fluid (BALF). "
5.	Hypoxia (Hypoxemia) 01/01/2019 - "The effects of BC-1215 on human alveolar epithelial cells subjected to hypoxia-reoxygenation (H/R) were also examined. "

1.	TNF Receptor-Associated Factor 2 (TRAF2)
2.	Proteins (Proteins, Gene)
3.	coactivator-associated arginine methyltransferase 1